Systematic genetic and genomic analysis of cytochrome P450 enzyme activities in human liver

Genome Research

Volumn 20, Issue 8, 2010, Pages 1020-1036

  Yang, Xia ^a,i   Zhang, Bin ^a,i   Molony, Cliona ^a   Chudin, Eugene ^a   Hao, Ke ^a   Zhu, Jun ^a,i   Gaedigk, Andrea ^b   Suver, Christine ^a,i   Zhong, Hua ^a,i   Leeder, J Steven ^b   Guengerich, F Peter ^c   Strom, Stephen C ^d   Schuet, Erin ^e   Rushmore, Thomas H ^f   Ulrich, Roger G ^g   Slatter, J Greg ^h   Schadt, Eric E ^a,j   Kasarskis, Andrew ^a,i   Lum, Pek Yee ^a,k  

^a ROSETTA INPHARMATICS   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g Calistoga Pharmaceuticals Inc   (United States)

^h AMGEN INC   (United States)

ⁱ SAGE BIONETWORKS   (United States)

^j PACIFIC BIOSCIENCES   (United States)

^k IPierian Inc   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B6; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4;

ADOLESCENT; ADULT; AGED; AKR1D1 GENE; ARTICLE; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; EHHADH GENE; ENZYME ACTIVITY; FEMALE; GENE; GENE CONTROL; GENE FUNCTION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; INFANT; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; NEWBORN; PHYLOGENETIC TREE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; SLC10A1 GENE; TRANSCRIPTION REGULATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENOME-WIDE ASSOCIATION STUDY; GENOMICS; HUMANS; INFANT; INFANT, NEWBORN; LIVER; MALE; MICE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; RATS; SYSTEMS BIOLOGY; TRANSCRIPTION, GENETIC; YOUNG ADULT;

RATTUS;

EID: 77955147593     PISSN: 10889051     EISSN: 15495469     Source Type: Journal    
DOI: 10.1101/gr.103341.109     Document Type: Article

References (97)

1. Adonis M, Martinez V, Marin P, Berrios D, Gil L. 2005. Smoking habit and genetic factors associated with lung cancer in a population highly exposed to arsenic. Toxicol Lett 159: 32-37. (Pubitemid 41317224)
2. Aguiar M, Masse R, Gibbs BF. 2005. Regulation of cytochrome P450 by posttranslational modification. Drug Metab Rev 37: 379-404. (Pubitemid 40677509)
3. Ahluwalia A, Clodfelter KH, Waxman DJ. 2004. Sexual dimorphism of rat liver gene expression: Regulatory role of growth hormone revealed by deoxyribonucleic acid microarray analysis. Mol Endocrinol 18: 747-760. (Pubitemid 38328217)
4. Aitken AE, Richardson TA, Morgan ET. 2006. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol 46: 123-149.
5. Anderson GD. 2008. Gender differences in pharmacological response. Int Rev Neurobiol 83: 1-10.
6. Anderson JL, Carlquist JF, Horne BD, Muhlestein JB. 2003. Cardiovascular pharmacogenomics: Current status, future prospects. J Cardiovasc Pharmacol Ther 8: 71-83.
7. Audet-Walsh E, Anderson A. 2008. Dexamethasone induction of murine CYP2B genes requires the glucocorticoid receptor. Drug Metab Dispos 37: 580-588.
8. Barbier O, Fontaine C, Fruchart JC, Staels B. 2004. Genomic and nongenomic interactions of PPARalpha with xenobiotic-metabolizing enzymes. Trends Endocrinol Metab 15: 324-330. (Pubitemid 39180007)
9. Barouki R, Morel Y. 2001. Repression of cytochrome P450 1A1 gene expression by oxidative stress: Mechanisms and biological implications. Biochem Pharmacol 61: 511-516. (Pubitemid 32178484)
10. Braeuning A. 2009. Regulation of cytochrome p450 expression by Ras- and β-catenin-dependent signaling. Curr Drug Metab 10: 138-158.
11. Cai Y, Konishi T, Han G, Campwala KH, French SW, Wan YJ. 2002. The role of hepatocyte RXRα in xenobiotic-sensing nuclear receptor-mediated pathways. Eur J Pharm Sci 15: 89-96. (Pubitemid 34136972)
12. Chavarria-Soley G, Sticht H, Aklillu E, Ingelman-Sundberg M, Pasutto F, Reis A, Rautenstrauss B. 2008. Mutations in CYP1B1 cause primary congenital glaucoma by reduction of either activity or abundance of the enzyme. Hum Mutat 29: 1147-1153.
13. Chen Y, Zhu J, Lum PY, Yang X, Pinto S, MacNeil DJ, Zhang C, Lamb J, Edwards S, Sieberts SK, et al. 2008. Variations in DNA elucidate molecular networks that cause disease. Nature 452: 429-435.
14. Daly AK. 2004. Pharmacogenetics of the cytochromes P450. Curr Top Med Chem 4: 1733-1744.
15. Davey Smith G, Ebrahim S. 2003. "Mendelian randomization": Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32: 1-22.
16. Debose-Boyd RA. 2007. A helping hand for cytochrome p450 enzymes. Cell Metab 5: 81-83.
17. Dhir RN, Dworakowski W, Thangavel C, Shapiro BH. 2006. Sexually dimorphic regulation of hepatic isoforms of human cytochrome p450 by growth hormone. J Pharmacol Exp Ther 316: 87-94.
18. Eloranta JJ, Kullak-Ublick GA. 2005. Coordinate transcriptional regulation of bile acid homeostasis and drug metabolism. Arch Biochem Biophys 433: 397-412.
19. Emilsson V, Thorleifsson G, Zhang B, Leonardson AS, Zink F, Zhu J, Carlson S, Helgason A, Walters GB, Gunnarsdottir S, et al. 2008. Genetics of gene expression and its effect on disease. Nature 452: 423-428.
20. Fan LQ, You L, Brown-Borg H, Brown S, Edwards RJ, Corton JC. 2004. Regulation of phase I and phase II steroid metabolism enzymes by PPARα activators. Toxicology 204: 109-121.
21. Fraser HB, Moses AM, Schadt EE. 2010. Evidence for widespread adaptive evolution of gene expression in budding yeast. Proc Natl Acad Sci 107: 2977-2982.
22. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. 2008. The CYP2D6 activity score: Translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83: 234-242.
23. Gargalovic PS, Imura M, Zhang B, Gharavi NM, Clark MJ, Pagnon J, Yang WP, He A, Truong A, Patel S, et al. 2006. Identification of inflammatory gene modules based on variations of human endothelial cell responses to oxidized lipids. Proc Natl Acad Sci 103: 12741-12746.
24. Gerbal-Chaloin S, Daujat M, Pascussi JM, Pichard-Garcia L, Vilarem MJ, Maurel P. 2002. Transcriptional regulation of CYP2C9 gene. Role of glucocorticoid receptor and constitutive androstane receptor. J Biol Chem 277: 209-217.
25. Ghazalpour A, Doss S, Zhang B, Wang S, Plaisier C, Castellanos R, Brozell A, Schadt EE, Drake TA, Lusis AJ, et al. 2006. Integrating genetic and network analysis to characterize genes related to mouse weight. PLoS Genet 2: e130. doi: 10.1371/journal.pgen.0020130.
26. Gibbs RA, Weinstock GM, Metzker ML, Muzny DM, Sodergren EJ, Scherer S, Scott G, Steffen D, Worley KC, Burch PE, et al. 2004. Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature 428: 493-521.
27. Gnerre C, Blattler S, Kaufmann MR, Looser R, Meyer UA. 2004. Regulation of CYP3A4 by the bile acid receptor FXR: Evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics 14: 635-645.
28. Gnerre C, Schuster GU, Roth A, Handschin C, Johansson L, Looser R, Parini P, Podvinec M, Robertsson K, Gustafsson JA, et al. 2005. LXR deficiency and cholesterol feeding affect the expression and phenobarbital-mediated induction of cytochromes P450 in mouse liver. J Lipid Res 46: 1633-1642.
29. Gonzalez FJ. 2008. Regulation of hepatocyte nuclear factor 4α-mediated transcription. Drug Metab Pharmacokinet 23: 2-7.
30. Gorski JC, Vannaprasaht S, Hamman MA, Ambrosius WT, Bruce MA, Haehner-Daniels B, Hall SD. 2003. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity. Clin Pharmacol Ther 74: 275-287.
31. Hakkola J, Tanaka E, Pelkonen O. 1998. Developmental expression of cytochrome P450 enzymes in human liver. Pharmacol Toxicol 82: 209-217. (Pubitemid 28270559)
32. Hardwick JP. 2008. Cytochrome P450 omega hydroxylase (CYP4) function in fatty acid metabolism and metabolic diseases. Biochem Pharmacol 75: 2263-2275.
33. He YD, Dai H, Schadt EE, Cavet G, Edwards SW, Stepaniants SB, Duenwald S, Kleinhanz R, Jones AR, Shoemaker DD, et al. 2003. Microarray standard data set and figures of merit for comparing data processing methods and experiment designs. Bioinformatics 19: 956-965.
34. Hodgson J. 2001. ADMET: Turning chemicals into drugs. Nat Biotechnol 19: 722-726.
35. Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, Felciano RM, Laurance MF, Zhao W, Qi S, Chen Z, et al. 2006. Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci 103: 17402-17407.
36. Huber WW, Rossmanith W, Grusch M, Haslinger E, Prustomersky S, Peter-Vorosmarty B, Parzefall W, Scharf G, Schulte-Hermann R. 2008. Effects of coffee and its chemopreventive components kahweol and cafestol on cytochrome P450 and sulfotransferase in rat liver. Food Chem Toxicol 46: 1230-1238. (Pubitemid 351258205)
37. Hughes AL, Powell DW, Bard M, Eckstein J, Barbuch R, Link AJ, Espenshade PJ. 2007. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab 5: 143-149. (Pubitemid 46172917)
38. Ishizawa Y, Yasui-Furukori N, Takahata T, Sasaki M, Tateishi T. 2005. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics. Clin Pharmacokinet 44: 1179-1189. (Pubitemid 41483702)
39. Jia Y, Qi C, Zhang Z, Hashimoto T, Rao MS, Huyghe S, Suzuki Y, Van Veldhoven PP, Baes M, Reddy JK. 2003. Overexpression of peroxisome proliferator-activated receptor-α (PPARα)-regulated genes in liver in the absence of peroxisome proliferation in mice deficient in both L- and D-forms of enoyl-CoA hydratase/dehydrogenase enzymes of peroxisomal β-oxidation system. J Biol Chem 278: 47232-47239. (Pubitemid 37452310)
40. Katz DA, Murray B, Bhathena A, Sahelijo L. 2008. Defining drug disposition determinants: A pharmacogenetic-pharmacokinetic strategy. Nat Rev Drug Discov 7: 293-305.
41. Koukouritaki SB, Manro JR, Marsh SA, Stevens JC, Rettie AE, McCarver DG, Hines RN. 2004. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 308: 965-974. (Pubitemid 38263972)
42. Krone N, Grischuk Y, Muller M, Volk RE, Grotzinger J, Holterhus PM, Sippell WG, Riepe FG. 2006. Analyzing the functional and structural consequences of two point mutations (P94L and A368D) in the CYP11B1 gene causing congenital adrenal hyperplasia resulting from 11-hydroxylase deficiency. J Clin Endocrinol Metab 91: 2682-2688. (Pubitemid 44024637)
43. Kuribayashi I, Kuge H, Santa RJ, Mutlaq AZ, Yamasaki N, Furuno T, Takahashi A, Chida S, Nakamura T, Endo F, et al. 2003. A missense mutation (GGC[435Gly]→AGC[Ser]) in exon 8 of the CYP11B2 gene inherited in Japanese patients with congenital hypoaldosteronism. Horm Res 60: 255-260. (Pubitemid 37465089)
44. Langfelder P, Zhang B, Horvath S. 2008. Defining clusters from a hierarchical cluster tree: The Dynamic Tree Cut package for R. Bioinformatics 24: 719-720. (Pubitemid 351321220)
45. Lee SS, Cha EY, Jung HJ, Shon JH, Kim EY, Yeo CW, Shin JG. 2008. Genetic polymorphism of hepatocyte nuclear factor-4α influences human cytochrome P450 2D6 activity. Hepatology 48: 635-645.
46. Lee WH, Lukacik P, Guo K, Ugochukwu E, Kavanagh KL, Marsden B, Oppermann U. 2009. Structure-activity relationships of human AKR-type oxidoreductases involved in bile acid synthesis: AKR1D1 and AKR1C4. Mol Cell Endocrinol 301: 199-204.
47. Lewis DF, Lee-Robichaud P. 1998. Molecular modelling of steroidogenic cytochromes P450 from families CYP11, CYP17, CYP19 and CYP21 based on the CYP102 crystal structure. J Steroid Biochem Mol Biol 66: 217-233. (Pubitemid 28401696)
48. Lim YP, Huang JD. 2008. Interplay of pregnane X receptor with other nuclear receptors on gene regulation. Drug Metab Pharmacokinet 23: 14-21.
49. Loeppen S, Koehle C, Buchmann A, Schwarz M. 2005. A β-catenin- dependent pathway regulates expression of cytochrome P450 isoforms in mouse liver tumors. Carcinogenesis 26: 239-248.
50. Lum PY, Chen Y, Zhu J, Lamb J, Melmed S, Wang S, Drake TA, Lusis AJ, Schadt EE. 2006. Elucidating the murine brain transcriptional network in a segregating mouse population to identify core functional modules for obesity and diabetes. J Neurochem 97: 50-62.
51. Masters B, Marohnic CC. 2006. Cytochromes P450: A family of proteins and scientists-understanding their relationships. Drug Metab Rev 38: 209-225.
52. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, et al. 2009. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360: 354-362.
53. Moon YJ, Wang X, Morris ME. 2006. Dietary flavonoids: Effects on xenobiotic and carcinogen metabolism. Toxicol In Vitro 20: 187-210.
54. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, et al. 1996. P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6: 1-42.
55. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. 2004. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics 14: 1-18.
56. Ortiz De Montellano PR. 2005. Cytochrome P450: Structure, mechanism, and biochemistry. Springer, New York.
57. Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll KM. 2004. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol 199: 193-209.
58. Peters CJ, Nugent T, Perry LA, Davies K, Morel Y, Drake WM, Savage MO, Johnston LB. 2007. Cosegregation of a novel homozygous CYP11B1 mutation with the phenotype of non-classical congenital adrenal hyperplasia in a consanguineous family. Horm Res 67: 189-193.
59. Plant N. 2007. The human cytochrome P450 sub-family: Transcriptional regulation, inter-individual variation and interaction networks. Biochim Biophys Acta 1770: 478-488.
60. Pullinger CR, Eng C, Salen G, Shefer S, Batta AK, Erickson SK, Verhagen A, Rivera CR, Mulvihill SJ, Malloy MJ, et al. 2002. Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 110: 109-117.
61. Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabasi A-L. 2002. Hierarchical organization ofmodularity inmetabolic networks. Science 297: 1551-1555. (Pubitemid 34971002)
62. Rinn JL, Snyder M. 2005. Sexual dimorphism in mammalian gene expression. Trends Genet 21: 298-305. (Pubitemid 40558936)
63. Saitoh T, Kokue E, Shimoda M. 2000. The impact of acute phase response on the plasma clearance of antipyrine, theophylline, phenytoin and nifedipine in rabbits. J Vet Pharmacol Ther 23: 153-158.
64. Scandlyn MJ, Stuart EC, Rosengren RJ. 2008. Sex-specific differences in CYP450 isoforms in humans. Expert Opin Drug Metab Toxicol 4: 413-424.
65. Schadt EE, Lamb J, Yang X, Zhu J, Edwards S, Guhathakurta D, Sieberts SK, Monks S, Reitman M, Zhang C, et al. 2005. An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet 37: 710-717.
66. Schadt EE, Molony C, Chudin E, Hao K, Yang X, Lum PY, Kasarskis A, Zhang B, Wang S, Suver C, et al. 2008. Mapping the genetic architecture of gene expression in human liver. PLoS Biol 6: e107. doi: 10.1371/journal.pbio.0060107.
67. Schrenk D, Schmitz HJ, Bohnenberger S, Wagner B, Worner W. 2004. Tumor promoters as inhibitors of apoptosis in rat hepatocytes. Toxicol Lett 149: 43-50. (Pubitemid 38469819)
68. Sekine S, Lan BY, Bedolli M, Feng S, Hebrok M. 2006. Liver-specific loss of beta-catenin blocks glutamine synthesis pathway activity and cytochrome p450 expression in mice. Hepatology 43: 817-825.
69. Seree E, Villard PH, Pascussi JM, Pineau T, Maurel P, Nguyen QB, Fallone F, Martin PM, Champion S, Lacarelle B, et al. 2004. Evidence for a new human CYP1A1 regulation pathway involving PPAR-α and 2 PPRE sites. Gastroenterology 127: 1436-1445. (Pubitemid 39457770)
70. Simon T, Becquemont L, Hamon B, Nouyrigat E, Chodjania Y, Poirier JM, Funck-Brentano C, Jaillon P. 2001. Variability of cytochrome P450 1A2 activity over time in young and elderly healthy volunteers. Br J Clin Pharmacol 52: 601-604.
71. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L. 2009. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360: 363-375.
72. Slatter JG, Templeton IE, Castle JC, Kulkarni A, Rushmore TH, Richards K, He Y, Dai X, Cheng OJ, Caguyong M, et al. 2006. Compendium of gene expression profiles comprising a baseline model of the human liver drug metabolism transcriptome. Xenobiotica 36: 938-962. (Pubitemid 44844109)
73. Stevens JC. 2006. New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology. Drug Discov Today 11: 440-445.
74. Stevens JC, Marsh SA, Zaya MJ, Regina KJ, Divakaran K, Le M, Hines RN. 2008. Developmental changes in human liver CYP2D6 expression. Drug Metab Dispos 36: 1587-1593.
75. Storey JD, Tibshirani R. 2003. Statistical significance for genomewide studies. Proc Natl Acad Sci 100: 9440-9445.
76. Strolin-Benedetti M, Brogin G, Bani M, Oesch F, Hengstler JG. 1999. Association of cytochrome P450 induction with oxidative stress in vivo as evidenced by 3-hydroxylation of salicylate. Xenobiotica 29: 1171-1180.
77. Tirona RG, Lee W, Leake BF, Lan LB, Cline CB, Lamba V, Parviz F, Duncan SA, Inoue Y, Gonzalez FJ, et al. 2003. The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 9: 220-224. (Pubitemid 36227725)
78. Tomaszewski P, Kubiak-Tomaszewska G, Pachecka J. 2008. Cytochrome P450 polymorphism-molecular, metabolic, and pharmacogenetic aspects. II. Participation of CYP isoenzymes in the metabolism of endogenous substances and drugs. Acta Pol Pharm 65: 307-318.
79. Vandel P, Talon JM, Haffen E, Sechter D. 2007. Pharmacogenetics and drug therapy in psychiatry: The role of the CYP2D6 polymorphism. Curr Pharm Des 13: 241-250. (Pubitemid 46085296)
80. van Schaik RH. 2005. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 23: 513-522. (Pubitemid 43162470)
81. Vasiliou V, Gonzalez FJ. 2008. Role of CYP1B1 in glaucoma. Annu Rev Pharmacol Toxicol 48: 333-358.
82. Wang K, Chen S, Xie W, Wan YJ. 2008. Retinoids induce cytochrome P450 3A4 through RXR/VDR-mediated pathway. Biochem Pharmacol 75: 2204-2213.
83. Wang K, Narayanan M, Zhong H, Tompa M, Schadt EE, Zhu J. 2009. Meta-analysis of inter-species liver co-expression networks elucidates traits associated with common human diseases. PLoS Comput Biol 5: e1000616. doi: 10.1371/journal.pcbi.1000616.
84. Wauthier V, Verbeeck RK, Calderon PB. 2007. The effect of ageing on cytochrome p450 enzymes: Consequences for drug biotransformation in the elderly. Curr Med Chem 14: 745-757. (Pubitemid 46477709)
85. Waxman DJ. 1999. P450 gene induction by structurally diverse xenochemicals: Central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys 369: 11-23.
86. Weng L, Dai H, Zhan Y, He Y, Stepaniants SB, Bassett DE. 2006. Rosetta error model for gene expression analysis. Bioinformatics 22: 1111-1121.
87. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K, Hamman MA, Hall SD, Wrighton SA. 2002. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos 30: 883-891. (Pubitemid 34815417)
88. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkovic D, Jhoti H. 2003. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424: 464-468. (Pubitemid 36917499)
89. Xie W, Tian Y. 2006. Xenobiotic receptor meets NF-κB, a collision in the small bowel. Cell Metab 4: 177-178. (Pubitemid 44283956)
90. Yang X, Schadt EE, Wang S, Wang H, Arnold AP, Ingram-Drake L, Drake TA, Lusis AJ. 2006. Tissue-specific expression and regulation of sexually dimorphic genes in mice. Genome Res 16: 995-1004. (Pubitemid 44162259)
91. Yang X, Deignan JL, Qi H, Zhu J, Qian S, Zhong J, Torosyan G, Majid S, Falkard B, Kleinhanz RR, et al. 2009. Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. Nat Genet 41: 415-423.
92. Zhang B, Horvath S. 2005. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol 4: Article17. doi: 10.2202/1544-6115.1128.
93. Zhou C, Tabb MM, Nelson EL, Grun F, Verma S, Sadatrafiei A, Lin M, Mallick S, Forman BM, Thummel KE, et al. 2006. Mutual repression between steroid and xenobiotic receptor and NF-κB signaling pathways links xenobiotic metabolism and inflammation. J Clin Invest 116: 2280-2289.
94. Zhu J, Lum PY, Lamb J, GuhaThakurta D, Edwards SW, Thieringer R, Berger JP, Wu MS, Thompson J, Sachs AB, et al. 2004. An integrative genomics approach to the reconstruction of gene networks in segregating populations. Cytogenet Genome Res 105: 363-374. (Pubitemid 38979700)
95. Zhu J, Wiener MC, Zhang C, Fridman A, Minch E, Lum PY, Sachs JR, Schadt EE. 2007. Increasing the power to detect causal associations by combining genotypic and expression data in segregating populations. PLoS Comput Biol 3: e69. doi: 10.1371/journal.pcbi.0030069.
96. Zhu J, Zhang B, Schadt EE. 2008a. A systems biology approach to drug discovery. Adv Genet 60: 603-635.
97. Zhu J, Zhang B, Smith EN, Drees B, Brem RB, Kruglyak L, Bumgarner RE, Schadt EE. 2008b. Integrating large-scale functional genomic data to dissect the complexity of yeast regulatory networks. Nat Genet 40: 854-861. (Pubitemid 351913653)